ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $3,364 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $57,580 | $52,193 |
| Gross Profit | $0 | $0 | -$57,580 | -$48,829 |
| % Margin | – | – | – | -1,451.5% |
| R&D Expenses | $19,907 | $45,100 | $57,580 | $52,193 |
| G&A Expenses | $13,887 | $15,101 | $14,970 | $17,164 |
| SG&A Expenses | $13,887 | $15,101 | $14,970 | $17,164 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$6,647 | -$3,686 | -$3,718 | -$5,283 |
| Operating Expenses | $27,147 | $56,515 | $68,832 | $64,074 |
| Operating Income | -$2,796 | -$56,515 | -$68,832 | $5,283 |
| % Margin | – | – | – | 157% |
| Other Income/Exp. Net | $3,089 | $2,720 | -$4,465 | -$67,942 |
| Pre-Tax Income | $293 | -$53,795 | -$73,297 | -$62,660 |
| Tax Expense | $521 | $2 | $3 | -$1 |
| Net Income | -$228 | -$53,797 | -$73,300 | -$62,659 |
| % Margin | – | – | – | -1,862.6% |
| EPS | -0.007 | -2.27 | -3.99 | -3.49 |
| % Growth | 99.7% | 43.1% | -14.3% | – |
| EPS Diluted | -0.007 | -2.27 | -3.99 | -3.49 |
| Weighted Avg Shares Out | 31,016 | 23,692 | 18,387 | 17,938 |
| Weighted Avg Shares Out Dil | 31,016 | 23,692 | 18,387 | 17,938 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,453 | $13 | $889 | $2,947 |
| Interest Expense | $1,364 | $2,138 | $5,354 | $1,533 |
| Depreciation & Amortization | -$19,898 | $5,377 | $889 | $2,947 |
| EBITDA | -$22,694 | -$46,280 | -$67,054 | $11,177 |
| % Margin | – | – | – | 332.3% |